迷幻藥市場：按藥物類型、應用、分銷管道、給藥途徑和地區分類

2026年，迷幻藥市場規模估計為44億美元，預計2033年將達到110.7億美元。預計從2026年到2033年，其複合年成長率將達到14.0%。

近年來，全球迷幻藥市場經歷了顯著成長，這主要歸功於人們越來越接受使用迷幻藥進行心理治療來治療精神疾病。迷幻藥，例如麥角酸二乙醯胺（LSD）、裸蓋菇素、3,4-甲基安非他命（MDMA）、氯胺酮和分離性藥物，用於改變使用者的感知、思考和意識層級。憂鬱症和其他精神疾病盛行率的上升，以及評估迷幻藥治療各種精神疾病療效的臨床研究數量的增加，是推動市場成長的主要因素。此外，北美和歐洲一些國家政府推出的有利監管改革也對迷幻藥療法在治療難治性憂鬱症疾病方面的應用產生了積極影響。

市場動態

全球迷幻藥市場成長的主要促進因素包括精神疾病盛行率上升、迷幻藥相關藥物的持續研發和臨床研究，以及醫師和病患對迷幻藥輔助心理療法的接受度不斷提高。根據世界衛生組織估計，全球有超過2.64億人患有憂鬱症。諸如裸蓋菇素、LSD和MDMA等迷幻藥在治療重度憂鬱症和其他精神疾病方面展現出潛力。越來越多的臨床研究正在評估這些藥物對難治性憂鬱症（TRD）和創傷後壓力症候群（PTSD）等疾病的治療效果，從而推動市場成長。此外，一些已開發國家的支持性法規結構也促進了迷幻藥的商業化。然而，對這些藥物臨床和商業性用途的嚴格監管對市場構成潛在挑戰。此外，娛樂性用途合法化的風險也可能阻礙迷幻藥在治療領域的應用。另一方面，促進研究和發展以建立循證治療模式，為該市場的相關人員提供了機會。

本次調查的主要特點

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
• 本研究根據以下參數對全球迷幻藥市場的主要參與者進行了分析：公司亮點、產品系列、主要特點、財務表現和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球迷幻藥市場報告的目標受群眾外包括產業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過用於分析全球迷幻藥市場的各種策略矩陣輕鬆做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 機會
• 影響分析
• 主要進展
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章 全球迷幻藥市場：依藥物類型分類，2021-2033年

• γ-羥基丁酸酯（GHB）
• 氯胺酮
• 裸蓋菇素
• 麥角酸二乙醯胺（LSD）
• 3,4-亞甲基安非他命（MDMA）
• 其他藥物類型（例如麥司卡林）

第5章 全球迷幻藥市場：依應用領域分類，2021-2033年

• 精神健康障礙
• 神經病變
• 疼痛管理
• 其他用途

第6章 全球迷幻藥市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球迷幻藥市場：依給藥途徑分類，2021-2033年

• 口服
• 靜脈
• 吸入
• 鼻內
• 其他（直腸）

第8章 全球迷幻藥市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第9章 競爭情勢

• MindMed
• Compass Pathways
• Cybin Inc.
• Atai Life Sciences
• Field Trip Health Ltd.
• Havn Life Sciences
• Revive Therapeutics
• NeonMind Biosciences
• Numinus Wellness
• PharmaTher Holdings Ltd.
• Jazz Pharmaceuticals
• Seelos Therapeutics
• NRx Pharmaceuticals Inc.
• Psyched Wellness Ltd.
• Silo Wellness

第10章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map

第11章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Psychedelic Drugs Market is estimated to be valued at USD 4.40 Bn in 2026 and is expected to reach USD 11.07 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.0% from 2026 to 2033.

The global psychedelic drugs market has witnessed significant growth in the past few years due to the increasing acceptance of psychedelic-assisted psychotherapy for the treatment of mental health conditions. Psychedelic drugs such as lysergic acid diethylamide (LSD), psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), ketamine, and dissociative drugs are used to alter users' perceptions, thoughts, and consciousness levels. Increasing prevalence of depression and other mental disorders as well as growing number of clinical research to evaluate the efficacy of psychedelic drugs for treatment of various mental health disorders is primarily driving the market growth. Moreover, favorable regulatory reforms by several governments across North America and Europe have positively impacted the adoption of psychedelic therapeutics for treatment of conditions such as treatment-resistant depression.

Market Dynamics

The global psychedelic drugs market growth is primarily driven by factors such the increasing prevalence of mental disorders, ongoing drug development and clinical research related to psychedelic drugs, and growing acceptance of psychedelic-assisted psychotherapy among physicians and patients. According to the WHO estimates, over 264 million people suffer from depression globally. Psychedelic drugs such as psilocybin, LSD, and MDMA have shown potential for the treatment of major depressive disorder as well as other mental health conditions. The growing number of clinical studies to evaluate the therapeutic effects of these drugs for conditions like treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD) is fostering the market growth. Additionally, supportive regulatory framework in several developed economies is enabling the commercialization of psychedelic medicines. However, strict regulations regarding the clinical and commercial use of these drugs pose potential challenges for the market. Moreover, risk of legalized recreational use can restrain the therapeutic adoption of psychedelic drugs. Meanwhile, the development of evidence-based treatment paradigms by facilitating research and innovation represents an opportunity for stakeholders in this market.

Key features of the study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global psychedelic drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include MindMed, Compass Pathways, Cybin Inc., Atai Life Sciences, Field Trip Health Ltd., Havn Life Sciences, Revive Therapeutics, NeonMind Biosciences, Numinus Wellness, PharmaTher Holdings Ltd., Jazz Pharmaceuticals, Seelos Therapeutics, NRx Pharmaceuticals Inc., Psyched Wellness Ltd., and Silo Wellness,
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global psychedelic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global psychedelic drugs market.

Market Segmentation

• By Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
• Gamma Hydroxybutyric Acid (GHB)
• Ketamine
• Psilocybin
• Lysergic Acid Diethylamide (LSD)
• 3,4-Methylenedioxymethamphetamine (MDMA)
• Other Drug Types (Mescaline, etc.)
• By Application Insights (Revenue, USD Bn, 2021 - 2033)
• Mental Health Disorders
  • Depression
  • Anxiety
  • PTSD (Post-Traumatic Stress Disorder)
  • Substance Use Disorders
• Neurological Disorders
  • Alzheimer's Disease
  • Parkinson's Disease
• Pain Management:
  • Chronic Pain
  • Migraines
• Other Applications:
  • Obsessive-Compulsive Disorder (OCD)
  • Others (Opiate Addiction, etc.)
• By Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• By Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
• Oral
• Intravenous
• Inhalation
• Intranasal
• Others (Rectal)
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• MindMed
• Compass Pathways
• Cybin Inc.
• Atai Life Sciences
• Field Trip Health Ltd.
• Havn Life Sciences
• Revive Therapeutics
• NeonMind Biosciences
• Numinus Wellness
• PharmaTher Holdings Ltd.
• Jazz Pharmaceuticals
• Seelos Therapeutics
• NRx Pharmaceuticals Inc.
• Psyched Wellness Ltd.
• Silo Wellness

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Psychedelic Drugs Market, By Drug Type
  • Global Psychedelic Drugs Market, By Application
  • Global Psychedelic Drugs Market, By Distribution Channel
  • Global Psychedelic Drugs Market, By Route of Administration
  • Global Psychedelic Drugs Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

• Market Dynamics
  • Driver
  • Restraint
  • Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Psychedelic Drugs Market, By Drug Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Gamma Hydroxybutyric Acid (GHB)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Ketamine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Psilocybin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Lysergic Acid Diethylamide (LSD)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• 3,4-Methylenedioxymethamphetamine (MDMA)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Other Drug Types (Mescaline, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Psychedelic Drugs Market, By Application, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Mental Health Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Depression
    • Anxiety
    • PTSD (Post-Traumatic Stress Disorder)
    • Substance Use Disorders
• Neurological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Alzheimer's Disease
    • Parkinson's Disease
• Pain Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Chronic Pain
    • Migraines
• Other Applications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Obsessive-Compulsive Disorder (OCD)
    • Others (Opiate Addiction, etc.)

6. Global Psychedelic Drugs Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Psychedelic Drugs Market, By Route of Administration, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Inhalation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Intranasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (Rectal)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Psychedelic Drugs Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• MindMed
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Compass Pathways
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cybin Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Atai Life Sciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Field Trip Health Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Havn Life Sciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Revive Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• NeonMind Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Numinus Wellness
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• PharmaTher Holdings Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Jazz Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Seelos Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• NRx Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Psyched Wellness Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Silo Wellness
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us